Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 14Oropharyngeal Neoplasms 12Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Mouth Neoplasms 8Laryngeal Neoplasms 8Carcinoma 8Small Cell Lung Carcinoma 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Nasopharyngeal Carcinoma 6Hypopharyngeal Neoplasms 6Pancreatic Neoplasms 5Mesothelioma, Malignant 5Triple Negative Breast Neoplasms 4Medulloblastoma 4Ganglioneuroblastoma 4Gallbladder Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Neuroblastoma 3Lymphoid Interstitial Pneumonia 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Adenocarcinoma of Lung 3Testicular Neoplasms 2

Interventions

Injections 2Infusions, Intravenous 2tislelizumab 1sacituzumab govitecan 1bintrafusp alfa protein, human 1Tomography, X-Ray Computed 1Platinum 1Nivolumab 1Ipilimumab 1Iodine-125 1Electrocardiography 1Echocardiography 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Platinum × 1 year × Clear all
NCT07272590 2025-12-09

Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
290 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡